Management attributes performance to a highly differentiated strategy focusing on the underserved U.S. cannabis industry and lower middle markets, which provides uncorrelated credit opportunities.

The portfolio is intentionally insulated from broader private credit pressures, with only 3% exposure to the software industry and zero exposure to recent high-profile fraud in syndicated facilities.

Yield superiority is driven by limited lending competition in niche sectors, resulting in a 15.8% weighted-average yield compared to the 10.8% BDC industry average.

Strategic asset protection is maintained through a 99.5% senior secured portfolio composition, significantly higher than the industry average of 24.9% for subordinated or equity-linked investments.

Interest rate resilience is a core structural feature, with 73% of the portfolio at par being either fixed-rate or at floating-rate floors, limiting NII impact from rate drops.

The company maintains a conservative leverage profile with a 0.08x debt-to-equity ratio, providing significant 'offensive' capacity compared to peers currently managing defensive positions.

The potential federal rescheduling of cannabis to Schedule III is expected to dramatically increase borrower cash flow and equity valuations, though the company manages the business assuming no regulatory change.

Management anticipates increased M&A and capital expenditure activity in the cannabis sector, which is already expanding the 2026 deal pipeline.

The platform reports a $732.0 million total pipeline, with $616.0 million in cannabis and $116.0 million in non-cannabis opportunities as of quarter end.

Future growth will prioritize disciplined sourcing and first-lien senior secured structures over chasing competitive, sponsor-driven deals that may compromise underwriting standards.

Guidance assumes continued utilization of the $100.0 million credit facility and potential exploration of unsecured financing to support strategic deployment.

Net investment income was impacted by the absence of $2.0 million in one-time fees from unscheduled repayments that occurred in the previous quarter.

The company reported zero nonaccruals as of year-end, contrasting with a 3.3% industry average, which management cites as evidence of rigorous internal due diligence.

A significant $38.3 million refinance for the company's largest borrower was executed as a bespoke 'first-out/last-out' financing in partnership with a large financial institution.

Recent repayment activity is characterized as idiosyncratic and reflective of accelerated transaction and consolidation volume within the cannabis market.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management noted that while formal rescheduling is pending, the prospect has already spurred optimism and consolidation activity among larger players.

Operators who previously stayed on the sidelines due to low valuations are now increasingly considering exits or growth investments.

The non-cannabis portfolio is designed to be more diversified with a higher number of smaller positions compared to the cannabis side.

Cannabis loans typically involve larger individual positions due to the nature of the operators and the capital-intensive industry requirements.

Chicago Atlantic utilizes third-party valuation providers for every position every quarter, rather than the industry standard of once per year per position.

This approach is intended to provide more consistent and transparent book value reporting for investors.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.